Introduction to Pazotab 200 mg (Pazopanib)
Pazotab 200 mg, containing the active ingredient Pazopanib, is a multi-tyrosine kinase inhibitor used for treating advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS) in patients who have undergone prior chemotherapy. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied by Saif Pharma, this medication plays a crucial role in targeted cancer therapy by inhibiting tumor growth and angiogenesis.
Key Indications & Therapeutic Benefits
- Advanced Renal Cell Carcinoma (RCC): Pazotab is approved for advanced kidney cancer, helping to slow tumor progression.
- Soft Tissue Sarcoma (STS): Effective for STS patients who have previously received chemotherapy (excluding adipocytic STS & GIST).
- Mechanism of Action: Inhibits VEGFR, PDGFR, FGFR, and c-Kit receptors, disrupting blood supply to tumors.
Pharmacology & Pharmacokinetics
- Absorption: Peak plasma levels achieved in 2-4 hours after oral intake.
- Distribution: Over 99% plasma protein-bound, with minimal renal excretion.
- Metabolism: Primarily metabolized by CYP3A4 enzyme (minor role of CYP1A2 & CYP2C8).
- Half-Life: Approximately 30.9 hours, allowing once-daily dosing.
Recommended Dosage & Administration
- Standard Dose: 800 mg once daily on an empty stomach (1 hour before or 2 hours after meals).
- Missed Dose: Skip if next dose is within 12 hours.
- Crushing Tablets: Avoid crushing to prevent altered absorption rates.
- Dose Adjustments:
- With CYP3A4 inhibitors (e.g., Ketoconazole): Reduce to 400 mg.
- With CYP3A4 inducers (e.g., Rifampin): Avoid concurrent use.
Drug Interactions & Precautions
- Strong CYP3A4 Inhibitors: Increase Pazotab levels (avoid grapefruit).
- CYP3A4 Inducers: Decrease Pazotab efficacy (avoid Rifampin).
- P-gp/BCRP Inhibitors: May elevate Pazotab exposure (use alternatives).
- Simvastatin Interaction: Higher risk of ALT elevation; monitor liver enzymes.
Contraindications & Safety Warnings
- Hypersensitivity: Avoid if allergic to Pazopanib.
- Hepatic Toxicity: Risk of liver damage; monitor ALT/AST regularly.
- QT Prolongation: Caution in patients with heart conditions.
- Hypertension: Blood pressure monitoring required.
- Pregnancy & Lactation: Contraindicated – may cause fetal harm.
Common Side Effects
- Hepatotoxicity (elevated liver enzymes)
- Hypertension, QT prolongation
- Fatigue, diarrhea, nausea
- Bleeding disorders, proteinuria
- Hypothyroidism, hair discoloration
Storage & Handling
- Store below 30°C in a dry place, away from sunlight.
- Keep out of children’s reach.
Why Choose Pazotab from Saif Pharma?
Saif Pharma is a trusted global supplier of oncology medicines, delivering high-quality, affordable cancer treatments to over 60+ countries, including the USA, Canada, UAE, and India. Our mission is to provide life-saving medications with reliable efficacy and safety.
Manufacturer & Supplier Details
- Manufacturer: Eskayef Pharmaceuticals Ltd. (A Transcom Group Company)
- Supplier: Saif Pharma – Specialized in oncology medicines since 2014.
Conclusion
Pazotab 200 mg (Pazopanib) is a potent anti-cancer drug for RCC and STS, backed by clinical efficacy and rigorous quality standards. For authentic supply, trust Saif Pharma – your global oncology medicine partner.
